Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection

Trial Profile

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs Valaciclovir (Primary)
  • Indications Hepatitis C; Herpes simplex virus type 2 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 15 Dec 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 May 2015 Planned End Date changed from 1 Mar 2015 to 1 Mar 2016, as reported by ClinicalTrials.gov (NCT01453075).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top